Long-term safety and efficacy of sirolimus-eluting stents in japanese patients: A single-center cohort study

Journal of Invasive Cardiology

Volumn 21, Issue 10, 2009, Pages 526-531

  Nakamura, Michinari ^a   Yamashita, Takeshi ^a   Yajima, Junji ^a   Oikawa, Yuji ^a   Ogasawara, Ken ^a   Kirigaya, Hajime ^a   Nagashima, Kazuyuki ^a   Sawada, Hitoshi ^a   Aizawa, Tadanori ^a  

^a THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

Cohort study; Intravascular ultrasound; Japanese; Sirolimus eluting stents

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; NITRATE; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BARE METAL STENT; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; HAZARD RATIO; HUMAN; IMPLANTATION; INCIDENCE; INTRAVASCULAR ULTRASOUND; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; REVASCULARIZATION; STATISTICAL SIGNIFICANCE; STENT THROMBOSIS;

AGED; ANTI-BACTERIAL AGENTS; CEREBRAL HEMORRHAGE; COHORT STUDIES; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; STENTS; THROMBOSIS; TREATMENT OUTCOME;

EID: 72649084964     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drugeluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591.
2. Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-2092.
3. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008;52:1134-1140.
4. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
5. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxeleluting coronary stents. N Engl J Med 2007;356:998-1008.
6. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. Eur Heart J 2006;27:2784-2814.
7. Stone GW, Ellis SG, Colombo A, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation 2007;115:2842-2847.
8. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
9. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997.
10. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007;370:937-948.
11. Williams DO, Abbott JD, Kip KE; for the DEScover Investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: Report of the DEScover Registry. Circulation 2006;114:2154-2162.
12. Lagerqvist B, James SK, Stenestrand U, et al; SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
13. Abbott JD, Voss MR, Nakamura M, et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: Findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007;50:2029-2036.
14. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drugeluting stents for off-label indications. N Engl J Med 2008;358:342-352.
15. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402.
16. Shishehbor MH, Goel SS, Kapadia SR, et al. Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. J Am Coll Cardiol 2008;52:1041-1048.
17. Mauri L, Silbaugh TS, Wolf RE, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 2008;118:1817-1827.
18. Garg P, Normand SL, Silbaugh TS, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: Results from the Massachusetts Data Analysis Center Registry. Circulation 2008;118:2277-2285, 7p following 2285.
19. Takahashi S, Kaneda H, Tanaka S, et al. Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J 2007;71:226-228. (Pubitemid 46182697)
20. Kimura T, Mitsudou K, Nobuyoshi M, on behalf of the j-Cypher Registry Investigators. Preliminary One-Year Outcome After Sirolimus-eluting Stent Implantation. The j-Cypher Registry Update. Available at: http://www.fda.gov/ ohrms/dockets/ac/06/slides/2006- 4253oph1-10-Kimura.pdf#search='JCypher registry' Accessed March 14, 2009.
21. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-356.
22. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297:1992-2000.
23. Win HK, Caldera AE, Maresh K, et al; EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-2009.
24. Machecourt J, Danchin N, Lablanche JM, et al; EVASTENT Investigators. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: The EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007;50:501-508.
25. Park SJ, Kim YH. Current status of percutaneous coronary intervention with drugeluting stents in Asia. Circulation 2008;118:2730-2737.
26. Steg PG, Bhatt DL, Wilson PW, et al; REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-1206.
27. Costa MA, Angiolillo DJ, Tannenbaum M, et al; STLLR Investigators. Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). Am J Cardiol 2008;101:1704-1711.
28. Mehta SR, Yusuf S, Peters RJ, et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-533.
29. Steinhubl SR, Berger PB, Mann JT 3rd, et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411-2420.
30. Bhatt DL, Flather MD, Hacke W, et al.; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-1988.
31. Nakamura M, Yamashita T, Yajima J, et al. Impact of reduced renal function on prognosis in Japanese patients with coronary artery disease: A prospective cohort of Shinken Database 2007. Hypertens Res 2009 Aug 21. [Epub ahead of print].
32. Cutlip DE, Windecker S, Mehran R, et al; Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351.
33. Okabe T, Mintz GS, Buch AN, et al. Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol 2007;100:615-620.
34. Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: An intravascular ultrasound study. J Am Coll Cardiol 2005;45:995-998.
35. Mintz GS, Weissman NJ. Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol 2006;48:421-429.
36. Gaku N, Kengo T, Aoki J, et al. Clinical and angiographic outcomes of sirolimus-eluting stents implantation in Japanese patients in daily practice. Circ J 2006;70:1367-1371.
37. Chen MS, John JM, Chew DP, et al. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006;151:1260-1264.
38. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-754.
39. Romagnoli E, Sangiorgi GM, Cosgrave J, et al. Drug-eluting stenting: The case for post-dilation. JACC Cardiovasc Interv 2008;1:22-31.
40. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008;118:1138-1145.
41. Fukushima K, Kobayashi Y, Okuno T, et al. Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation. Circ J 2007;71:617-619.